这种脯氨酸特异性寡肽酶是利用转基因黑曲霉自克隆株产生的脯氨酸寡肽酶制剂。欧盟食品安全局专家组对这种脯氨酸特异性寡肽酶的安全性进行了评估。专家组经过评估认为，脯氨酸特异性寡肽酶无遗传毒性。它的目标使用人群为一般成年人，预期最大使用量为每天2746 mg TOS/人或39.2 mg TOS/kg 体重（默认一般成年人的体重为70KG）。
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies （NDA） was asked to deliver an opinion on proline-specific oligopeptidase （Tolerase G） as a novel food ingredient submitted pursuant to Regulation （EC） No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modified Aspergillus niger self clone strain. The target population is the general adult population. The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not indicate genotoxicity. The Panel considers that the reported effects observed in a 90-day rat study are treatment-related effects and can be attributed to the higher energy consumption by these animals. Taking into account the intended maximum use level for Tolerase G, its daily consumption would correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight （bw） per day, when considering a default body weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the Panel considers that it is unlikely that such effects would occur in human at the intended use levels. The Panel concludes that the NF, Tolerase G, is safe for the intended use at the intended use level.